Other Inhibitors

Culmerciclib is a cell cycle protein-dependent kinase (CDK) inhibitor that exhibits antitumour effects.

PAD4-IN-2 (compound 5i) is a PAD4 inhibitor with an IC50 value of 1.94 μM, shown to suppress tumor growth in mice through specific inhibition of the PAD4-H3cit-

PS372424 activates CXCR3, triggers ERK phosphorylation, and inhibits CXCL11's effect on CD45+ cell migration in humanized mice.

Antibacterial Agent 160 is a potent antibacterial agent that rapidly eradicates bacteria and inhibits the formation of bacterial biofilms.

Azilsartan medoxomil potassium (QR-01019K), an angiotensin II receptor antagonist, exhibits a potent and sustained antihypertensive effect, along with a more

CYY292 is a chemical compound acting as an inhibitor of PDGFRα, PDGFRβ, FGFR1, -2, and -3, with respective IC50 values of 5.35, 4.6, 28, 28, and 78 nM.

Sakura 6, a synthetic serotonin transporter (SERT)-binding peptide, enhances the interaction between SERT and neuronal nitric oxide synthase.

Immune cell migration-IN-1 (compound 2) serves as a potent inhibitor of immune cell migration, with potential research applications for mitigating conditions

80-O16B, an ionizable cationic lipid featuring disulfide bonds, is utilized in the preparation of lipid nanoparticles (LNP) [1].

Compound B12 (Antibacterial agent 157) is a fungicidal agent that can impact protein synthesis in Botrytis cinerea.

Civorebrutinib (WS-413) is an inhibitor of Bruton's tyrosine kinase that exhibits antineoplastic activity [1].

SHP2-IN-14 (compound 27) is a potent, orally active allosteric inhibitor of SHP2, displaying strong anti-tumor activity with an IC50 of 7 nM.

Anti-MI/R injury agent 1 (compound 18), derived from Panaxatriol, represents an orally administered, potent agent against myocardial ischemia/reperfusion (MI/R

Antitumor Photosensitizer-1 (Compound 8) is a potent photosensitizer with remarkable photodynamic anti-tumor properties and minimal skin photo-toxicity,

Tauro-obeticholic acid, a farnesoid X receptor (FXR) agonist and semisynthetic derivative of chenodeoxycholic acid, is an active metabolite of obeticholic acid.

BET-IN-1 is a bromodomain inhibitor extracted from patent WO/2013024104A1 (example 2, plC50: 6.0 - 7.0).

LT-540-717 (compound 32), a potent FLT3 inhibitor (IC50=0.62 nM), exhibits antiproliferative activity and effectively inhibits various acquired FLT3 mutations,

FLT3-IN-19 (Comp 50) is a potent, selective inhibitor of FLT3, demonstrating an IC50 value of 0.213 nM, and is applicable in research pertaining to acute

Compound 11, also known as Antitumor Photosensitizer-2, is a potent photosensitizer with remarkable photodynamic anti-tumor properties and minimal skin photo-

FAP-IN-2 is a 99mTc-labeled, isonitrile-containing derivative of a fibroblast activation protein (FAPI) inhibitor suitable for tumor imaging [1].

Antitumor Agent-136 (Compound 17), a broad-spectrum antitumor agent and NAMPT inhibitor, exhibits potent activity with an IC50 of 9.5 nM. It efficiently lowers intracellular and extracellular NAMPT protein levels via the ubiquitin proteasome pathway, achieving effective tumor inhibition [1].

S-72 acts as a microtubule polymerization inhibitor, effective in cell-free assays at concentrations of 1, 3, and 10 µM.

DiaFluo is a probe for protein S-sulfinylation from cells.

DDO-2213 is a potent, orally active inhibitor of the WDR5-MLL1 interaction, demonstrating an IC50 of 29 nM and a Kd of 72.9 nM against WDR5.

URAT1 Inhibitor 5 (compound 16) serves as a powerful inhibitor of URAT1 and is utilized in hyperuricemia research [1].

And1-IN-1, also known as compound III, is a potent inhibitor of And1 [1].

IDO/Tubulin-IN-2 inhibits TDO/tubulin, effective on U87, HepG2, A549, HCT-116, LO2 cancer cells; IC50 values 0.036-1.04 μM, boosts antitumor action.

PD1-PDL1-IN 2 (ZE132) is a potent, selective inhibitor of PD-1/PD-L1, exhibiting significant anti-tumor activity in vivo. It enhances cytotoxic T-cell tumor infiltration and stimulates IL-2 expression, while also strongly inhibiting TGF-β [1] mRNA expression, showcasing its comprehensive immunotherapeutic potential.

FOXM1-IN-2, a FOXM1 inhibitor, exhibits antineoplastic activity [1].

Ac4GalNAlk, a weakly alkyne-labeled reagent for metabolic oligosaccharide engineering (MOE), facilitates the detection of protein glycosylation by promoting nucleotide-sugar biosynthesis and enhancing bioorthogonal cell surface markers. It is activated by cellular biosynthetic machinery into nucleotide sugars, subsequently enabling the tracing of glycoproteins in bioorthogonal chemistry [1].

RIOK2-IN-2 (8) functions as an inhibitor of RIOK2, exhibiting IC50 values of 3.02 μM in MKN-1 cells and 5.34 μM in MOLT4 cells [1].

HPK1-IN-38 (compound 15) is an inhibitor of MAP4K1/HPK1, suitable for research into disorders related to HPK1 [1].

CIAC001, a pyruvate kinase PKM2 inhibitor, exhibits anti-neuroinflammatory properties.

LM2I, a derivative of Spinosyn A (SPA), serves both as an argininosuccinate synthase (ASS1) enzyme activator and a tumor inhibitor through direct interaction

Ifetroban sodium (BMS-180291), oral TXA2/PGH2 antagonist for researching heart, stroke, BP, thrombosis.

BPH-628 is a bioactive chemical.

Ifetroban is a potent and selective TxA2/PGH2 receptor antagonist.

9,10-Phenanthrenequinone is an inhibitor of claudin-5/CLDN5, which induces apoptosis via an NO synthase/ROS-dependent mechanism. It also promotes caspase activation and DNA fragmentation while reducing CLDN5 expression and proteasome proteolysis, contributing to endothelial barrier dysfunction.